H.C. Wainwright Reiterates Buy Rating on Evaxion Biotech (EVAX)

April 24, 2026 6:44 AM

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $16.00 price target on Evaxion Biotech (NASDAQ: EVAX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found